Biotechnology Companies in The Netherlands

In Ovo combines animal welfare and efficiency by offering biotechnological solutions to the poultry industry. We currently focus on a long existing problem in hatcheries: The culling of one day old male chickens. Our solution, a gender screening in the first half of the breeding process, has several advantages. It prevents a lot of stress the chickens experience during the current manual gender sorting process, it reduces the energy consumption and CO2 emission of the hatchery and prevents the need to kill one day old chickens. This way, we make hatcheries more animal friendly and sustainable, and increase the efficiency at the same time.

Allero Therapeutics is a Dutch, venture-backed, biopharmaceutical company that develops next generation immunotherapies for immune mediated disorders. Our goal is to develop novel targeted treatments that induce long-lasting antigen-specific tolerance. Our proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with novel oral patch mediated targeted delivery of specific antigens to the oral mucosa immune privilege.

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.

LUMICKS is the leading supplier of dynamic single-molecule and cell avidity analysis instruments. Our instruments enable – for the first time – the analysis of complex dynamic details related to the behavior and interaction of single molecules and cells. Built upon innovative and Nobel Prize-winning technologies, such as optical tweezers (Nobel Prize for Physics 2018), and STED super-resolution (Nobel Prize for Chemistry 2014), our tools enable the understanding of life to the smallest detail. Our goal is to advance science and improve human health, by providing tools that unlock the measurement of forces and interactions in biology. For the first time ever, our unapparelled solutions can assist research by directly linking structural and ‘omics analysis to functional outcomes at both a molecular and a cellular level. This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms.

Scenic Biotech is applying a novel approach to target discovery by harnessing genetic suppressors. Powered by our proprietary technology, Scenic scientists are obtaining a unique and more comprehensive understanding of disease biology. These insights enable us to rapidly identify and validate novel drug targets and then focus on the development of medicines with the greatest potential to impact the lives of patients.

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx’s first experimental medicine, efgartigimod, is being evaluated in multiple autoimmune diseases, including myasthenia gravis (MG), pemphigus vulgaris (PV), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). argenx is located in Ghent, Belgium, Boston, Massachusetts and Tokyo, Japan.

Our company has the purpose of bridging the gap between insects & food companies so we can create the future of food Now! “We believe in a greener and healthier future, and we know is possible by changing the base of production without waiting for consumer behavior to change. There is an urgent need for better, safer and more sustainable sources of food ingredients and materials for the food industry. We can do this using biotechnology & data science to unlock the potential of insects as ingredients, biomaterials & many more to be discovered.” Alejandro Ortega, CEO & Founder Daniela Arias, COO & Founder Inspired by their culture Daniela and Alejandro named the company after the primary deity in the Talamancan mythology of Costa Rica, is the creator of Earth and humanity, god of wisdom and taught the values using natural resources in a responsible way and with harmony. We help insect ingredient manufacturers meeting the requirements of food companies & food brands, which requires improving the qualify and functionality of their current materials using new and innovative process optimization technologies we develop. Together with this we focus on accelerating the innovation & development using data science for targeted ingredient discovery, to create clean, efficient, and sustainable insect-based bio-active components including protein, fats and chitosan, as highly functional food ingredients for food manufacturers. And we can do it thanks to our unique green Isolation technology called Entowise®, which unlocks the potential of insect-bioactive components and improves the application of these materials as ingredients for food production. The Entowise® technology helps insect manufacturers to develop high value added and easy to use ingredients for food manufactures. Our technology and approach help food manufacturer reduce CO2 emissions up to 95% compared with current alternatives, while also improve the health of their end consumer

At SkylineDx, we live to make a difference. It is our mission to improve a patient’s quality of life by enabling them to benefit from personal insights at the genomic level of their disease. That means we are continuously innovating the world of gene signature-based diagnostic testing. Genes are responsible for making us who we are. It can determine our features such hair and eye color, skin tone, or even height. Although we know our genetic make-up is similar to one another, each individual is vastly unique. “No two humans are alike.” And while most agree on the quote above, the contrary is being practiced in disease treatment today. When a patient gets a cancer diagnosis, he or she is treated, more or less, the same as other patients with the same type of cancer. For decades we have known, but were not able to determine why patients with the same diagnosis respond differently to the same treatment. Today, after years of genetic research, we know that like humans, no two cancer cells are alike. And for that reason, we now know cancer treatments should differ case by case, because cancer cells are inherently different. At SkylineDx, we have a team of experts with the knowledge and capability to collaborate with highly respected physicians and patients advocates. Together we work to achieve the same multi-disciplinary goal: to give physicians the genetic tools to better guide the most affective treatment plan for their patients. This principle of individualized treatment plans is called personalized- or precision medicine and is extremely important for the patient. With the right personalized treatment, at the right moment, the patient can avoid side effects from over or undertreatment, which means less hospitalization, complications, medications, and ultimately better quality of life.

We have developed an improved Monocyte Activation Test (MAT) for pyrogen testing. The MAT serves as the replacement for the Rabbit Pyrogen Test and can be used to test parenteral drugs for endotoxin and non-endotoxin contaminations. Our technology uses cryopreserved pooled PBMC. This has made it possible to develop a MAT with both high sensitivity and robustness, ensuring reliability in the field. Monocyte Activation Test (MAT) The Monocyte Activation Test (MAT) is a pyrogen test. MAT uses human blood cells to test for a fever reaction, mimicking the human immune reaction.The MAT serves as the replacement for the Rabbit Pyrogen Test and can be used to test parenteral drugs for endotoxin and non-endotoxin contaminations. Our technology uses cryopreserved pooled PBMC. This has made it possible to develop a MAT with both high sensitivity and robustness, ensuring reliability in the field. The MAT kit includes all the required consumables to perform the Monocyte Activation Test, making it convenient to perform. In addition to the kit we provide consulting services and technical support in setting up the MAT in your organisation.

Single Cell Discoveries is the leading single-cell sequencing CRO providing high-impact insights to biopharmaceutical companies, health systems, and academic research centers globally. We offer single-cell, spatial, and bulk transcriptomics. Our R&D team is actively developing novel single-cell sequencing technologies, multi-omic applications, and spatial transcriptomics.

AHV International is an innovative knowledge centre and leading developer of the Animal Health Vision Concept. Through our services and solutions, we strive to connect and support our sector on an international level. It is our mission as a sector to work together. AHV therefore wants to proactively support and relieve livestock farmers, veterinarians and companies within agriculture. We do this by developing various supplementary animal feeds on a natural and scientific basis, which support the resistance and welfare of your animal, as well as by providing extensive, transparent and expert services. We believe that with our Animal Health Vision Concept and AHV Solutions, together as an industry, we can achieve better care results within the entire animal health continuum: from the health and welfare of your animals, to tailored advice, education and (pre- and post-) care. For today, tomorrow and the future, so that together we can ensure that you and following generations of dairy farmers remain the driving force behind our society.

Iribov is an international plant breeding support laboratory founded in 1992, employing around 600 people in 4 locations: in The Netherlands (Heerhugowaard), Macedonia (Vinica), Ghana (Sogakope) and Brasil. The services of Iribov can be divided into 4 segments: 𝗣𝗹𝗮𝗻𝘁 𝗧𝗶𝘀𝘀𝘂𝗲 𝗖𝘂𝗹𝘁𝘂𝗿𝗲: Initiation, Virus Elimination, Naktuinbouw Elite certified production, Stock Maintainance, Protocol Development, Large Scale Propagation. 𝗕𝗿𝗲𝗲𝗱𝗶𝗻𝗴 𝗦𝘂𝗽𝗽𝗼𝗿𝘁: Gene Bank Storage in Tissue Culture, Interspecific crossing, Embryo Rescue, Mutation Induction, Dihaploid production, Polyploidization, Marker Assisted Breeding, Crispr-Cas (future development). 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝗮𝗹 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀: Plant pathogen detection (PCR), Seed quality control, Flowcytometry, Cytology, Biochemical Assays, Bioassays. Hardening: automated planting of tissue culture plants, vertical farm facilities, automated grading and sorting, various growing compartments and -specifications, tailor made growing solutions. The portfolio of Iribov covers over 450 plant species in 10.000 varieties for the ornamental horticulture, vegetable and (soft)fruit companies and the plantation industry worldwide.

Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of both rare and prevalent diseases. The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVero™) that, for the first time, makes it possible to produce SV40-derived vectors suitable for therapeutic use. Combining SuperVero™ with its genetically engineered SVec viral vector, the company’s fully-integrated gene therapy platform is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product. Leveraging this ‘natural’ non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe, effective and durable gene therapies focused on genetic disorders, autoimmune diseases and chronic inflammation. Founded in 2008, Amarna’s head office is based in Leiden Bio Science Park, the Netherlands, with a research subsidiary located in Seville, Spain.

As Spinoff of TNO, we develop integrated photonics to create highly sensitive and selective biosensors. These are an order of magnitude more affordable, measure multiple biomarkers and are extremely sensitive, reaching SPR sensitivity. Our chips and readout device can be used anywhere from medical research, agriculture to Point-of-Care diagnostic applications.

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31 2021 QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.

Get to know the bacteria that live in your own gut. Take control over your own health! www.mymicrozoo.com/nl

PHC Europe BV, part of the PHC Corporation, Biomedical Division, manages sales, marketing, logistics and technical service of PHCbi laboratory products throughout Europe (including Turkey). Headquartered in the Netherlands with sales and service organizations in the UK, France and the Netherlands. In the Dutch warehouse, about 1.000 units are waiting to be delivered directly from stock. Within a couple of days, spare parts can be delivered in every part of Europe. That’s one of the strengths of PHC's European sales organization. PHC has established a worldwide reputation as a manufacturer of high-quality and innovative medical and laboratory equipment over the past forty years. Long lasting relationships have been built with leading pharmaceutical, healthcare and biotechnology companies as well as with major academic and research institutes in Europe. In this field PHC has set the standard in many aspects. V.I.P. panels, Cool Safe compressors and the world’s first -152°C ULT freezer. Where PHC took the initiative, the others followed.